| scholarly article | Q13442814 |
| P50 | author | James J Sejvar | Q88977708 |
| P2093 | author name string | David B Clifford | |
| Eugene O Major | |||
| Avindra Nath | |||
| Joseph R Berger | |||
| Igor J Koralnik | |||
| Allen J Aksamit | |||
| Russell Bartt | |||
| Larry Davis | |||
| P2860 | cites work | Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy | Q24683776 |
| Progressive multifocal leukoencephalopathy in a patient treated with natalizumab | Q28255536 | ||
| Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis | Q28255548 | ||
| Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease | Q28255557 | ||
| Pathological correlates of magnetization transfer imaging abnormalities in animal models and humans with multiple sclerosis | Q30581839 | ||
| Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. | Q30583907 | ||
| The Evolving Face of Human Immunodeficiency Virus-Related Progressive Multifocal Leukoencephalopathy: Defining a Consensus Terminology | Q30787783 | ||
| Progressive multifocal leukoencephalopathy in patients with HIV infection | Q32073645 | ||
| Comparison of magnetic resonance imaging with neuropathological findings in the diagnosis of HIV and CMV associated CNS disease in AIDS | Q33735672 | ||
| Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons | Q33834119 | ||
| Quantification of human polyomavirus JC in brain tissue and cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy by competitive PCR. | Q33887332 | ||
| Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy | Q34041795 | ||
| Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy | Q34201921 | ||
| JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy | Q34405800 | ||
| Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease | Q34538727 | ||
| Immune reconstitution inflammatory syndrome in natalizumab-associated PML. | Q35215625 | ||
| Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. | Q35609239 | ||
| Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy | Q35634870 | ||
| Chronic basal meningitis and vasculitis in acquired immunodeficiency syndrome. A possible role for human immunodeficiency virus. | Q36417224 | ||
| Diagnostic value of detecting JC virus DNA in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy | Q36519031 | ||
| Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy | Q37028699 | ||
| JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab | Q37085051 | ||
| Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy | Q37088626 | ||
| Detection of BK virus and JC virus in urine and brain tissue by the polymerase chain reaction. | Q37174421 | ||
| Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. | Q37196796 | ||
| Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases | Q37714089 | ||
| Progressive multifocal leukoencephalopathy and newer biological agents | Q37798242 | ||
| Pathogenesis of progressive multifocal leukoencephalopathy--revisited | Q37828002 | ||
| Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8(+) T cells with JCV-infected glial cells | Q38437214 | ||
| A granule cell neuron-associated JC virus variant has a unique deletion in the VP1 gene | Q38961269 | ||
| PET scanning and the human immunodeficiency virus-positive patient. | Q40645891 | ||
| Varicella-zoster virus infection of the central nervous system in the acquired immune deficiency syndrome | Q43877258 | ||
| Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies | Q44417521 | ||
| Are astrocytes infected in progressive multifocal leukoencephalopathy (PML)? | Q44447475 | ||
| Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. | Q44832792 | ||
| Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients | Q45406699 | ||
| High sensitivity detection of JC-virus DNA in postmortem brain tissue by in situ PCR. | Q45742791 | ||
| Progressive multifocal leukoencephalopathy diagnosed by amplification of JC virus-specific DNA from cerebrospinal fluid. | Q45781555 | ||
| JC virus DNA in cerebrospinal fluid of human immunodeficiency virus—infected patients: Predictive value for progressive multifocal leukoencephalopathy | Q45786584 | ||
| Progressive multifocal leukoencephalopathy: JC virus detection by in situ hybridization compared with immunohistochemistry | Q45837042 | ||
| Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection | Q45839250 | ||
| Absence of thallium-201 brain uptake in progressive multifocal leukoencephalopathy in AIDS patients | Q48139791 | ||
| Intracranial mass lesions: sequential thallium and gallium scintigraphy in patients with AIDS. | Q48220887 | ||
| Angiographic abnormalities in progressive multifocal leukoencephalopathy: an explanation based on neuropathologic findings. | Q48225589 | ||
| Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation | Q48312431 | ||
| Progressive multifocal leukoencephalopathy with 10-year survival in a patient with nontropical sprue: Report of a case with unusual light and electron microscopic features | Q48430490 | ||
| Progressive multifocal leukoencephalopathy in HIV-1-infected children | Q48449974 | ||
| Progressive multifocal leukoencephalopathy (PML) mimicking high-grade glioma on delayed F-18 FDG PET imaging | Q48486132 | ||
| The efficacy of image-guided stereotactic brain biopsy in neurologically symptomatic acquired immunodeficiency syndrome patients | Q48539449 | ||
| Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy | Q48745765 | ||
| Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. | Q48789449 | ||
| Progressive multifocal leukoencephalopathy: its pathological features | Q48846642 | ||
| Magnetic resonance brain imaging lacks sensitivity for AIDS associated cytomegalovirus encephalitis. | Q48849011 | ||
| Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. | Q53517226 | ||
| Diagnosis of progressive multifocal leukoencephalopathy by stereotactic brain biopsy utilizing immunohistochemistry and the polymerase chain reaction | Q57189798 | ||
| Progressive multifocal leukoencephalopathy demonstrating contrast enhancement on MRI and uptake of thallium-201: a case report | Q57694305 | ||
| Progressive multifocal leukoencephalopathy | Q70682570 | ||
| Progressive multifocal leukoencephalopathy | Q76493778 | ||
| HIV and acute disseminated encephalomyelitis | Q77395270 | ||
| Reversible leukoencephalopathy in a patient with nucleoside analogue-associated mitochondrial DNA depletion and metabolic disease | Q78543971 | ||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | diagnosis | Q16644043 |
| P304 | page(s) | 1430-1438 | |
| P577 | publication date | 2013-04-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | |
| P478 | volume | 80 |
| Q48159926 | "All the soarings of my mind begin in my blood:" central nervous system complication of Waldenström macroglobulinemia |
| Q45069581 | "Neurological complications of new chemotherapy agents". |
| Q88601420 | A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials |
| Q59349114 | A Punctate Magnetic Resonance Imaging Pattern in a Patient with Systemic Lupus Erythematosus Is an Early Sign of Progressive Multifocal Leukoencephalopathy: A Clinicopathological Study |
| Q92343573 | A case of recurrent progressive multifocal leukoencephalopathy after human stem cell transplant, with detection of John Cunningham virus and human herpesvirus 6 on cerebrospinal fluid, treated with Mirtazapine, Olanzapine and Foscarnet |
| Q90657750 | A case of unexpected progressive multifocal leukoencephalopathy in a hemodialysis patient |
| Q44260772 | A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab |
| Q90234526 | A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy |
| Q33956020 | A fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient |
| Q58782181 | A loop-mediated isothermal amplification assay for the detection and quantification of JC polyomavirus in cerebrospinal fluid: a diagnostic and clinical management tool and technique for progressive multifocal leukoencephalopathy |
| Q40156474 | A prominent lactate peak as a potential key magnetic resonance spectroscopy (MRS) feature of progressive multifocal leukoencephalopathy (PML): Spectrum pattern observed in three patients |
| Q40100891 | Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy. |
| Q57281351 | Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy |
| Q90264199 | An unusual case of PML in HIV patient presenting with diplopia |
| Q40229429 | An unusual cause of fatal rapid-onset ataxia plus syndrome. |
| Q33814485 | Anaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromes |
| Q40565210 | Anti-JC virus seroprevalence in a Finnish MS cohort. |
| Q52659119 | Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. |
| Q52150367 | Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. |
| Q33810020 | Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study |
| Q90074405 | Brief Report: Decreased JC Virus-Specific Antibody-Dependent Cellular Cytotoxicity in HIV-Seropositive PML Survivors |
| Q37041199 | CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). |
| Q37442512 | Central nervous system immune reconstitution inflammatory syndrome. |
| Q40039772 | Cerebellar Involvement in an Immunocompetent Patient Presenting with Progressive Multifocal Leukoencephalopathy |
| Q34324861 | Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy |
| Q30250271 | Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls |
| Q48559860 | Clinical and MRI improvement in a case of progressive multifocal leukoencephalopathy. |
| Q26771635 | Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis |
| Q36783871 | Concomitant granule cell neuronopathy in patients with natalizumab-associated PML |
| Q26799201 | Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis |
| Q48217985 | Critical updates in the 7th edition of the American Society for Apheresis guidelines. |
| Q36073992 | Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab |
| Q39705818 | Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system |
| Q40039520 | Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies |
| Q88043052 | Diagnosis of Inclusion |
| Q42226607 | Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place? |
| Q36942417 | Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy |
| Q36891735 | Diagnostic delay in progressive multifocal leukoencephalopathy |
| Q41126166 | Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients |
| Q57562078 | Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions |
| Q30815289 | Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases |
| Q40543791 | Drug-induced progressive multifocal leukoencephalopathy: a case/noncase study in the French pharmacovigilance database |
| Q33428818 | Eculizumab-related progressive multifocal leukoencephalopathy |
| Q36318597 | Expression of Signaling Molecules in Progressive Multifocal Leukoencephalopathy |
| Q64255951 | Favorable Response to Mirtazapine in John Cunningham Virus-related Gray Matter Lesion in a Patient with Human Immunodeficiency Virus |
| Q42560354 | Finger pointing to JC virus: a tale of two indexes |
| Q51805924 | Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases. |
| Q91635987 | Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy |
| Q51762497 | Global HIV neurology: a comprehensive review. |
| Q92720553 | HIV-Related Cerebral Toxoplasmosis Revisited: Current Concepts and Controversies of an Old Disease |
| Q38992309 | HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment |
| Q35314514 | Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature |
| Q40342277 | High b-value diffusion-weighted imaging in progressive multifocal leukoencephalopathy in HIV patients. |
| Q54607295 | High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES. |
| Q97530394 | Human immunodeficiency virus-associated vacuolar encephalomyelopathy with granulomatous-lymphocytic interstitial lung disease improved after antiretroviral therapy: a case report |
| Q35931809 | Human polyomavirus receptor distribution in brain parenchyma contrasts with receptor distribution in kidney and choroid plexus. |
| Q35590449 | Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy |
| Q37256223 | Hyperperfusion in progressive multifocal leukoencephalopathy is associated with disease progression and absence of immune reconstitution inflammatory syndrome |
| Q38419557 | Imaging in Neurologic Infections II: Fungal and Viral Diseases. |
| Q33715659 | Immune Reconstitution Inflammatory Syndrome Unmasking or Worsening AIDS-Related Progressive Multifocal Leukoencephalopathy: A Literature Review |
| Q42209595 | Immune reconstitution disorders in patients with HIV infection: from pathogenesis to prevention and treatment. |
| Q37678580 | Immune surveillance and response to JC virus infection and PML. |
| Q34818048 | Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab |
| Q92153035 | Immunopathology of Fatal Human Variegated Squirrel Bornavirus 1 Encephalitis, Germany, 2011-2013 |
| Q55039421 | Immunophenotypic characterization of CSF B cells in virus-associated neuroinflammatory diseases. |
| Q30908652 | Infection risk in patients on multiple sclerosis therapeutics |
| Q92321106 | Inflammatory Cerebellar PML with a CD4/CD8 Ratio of 2.9 Showed a Favorable Prognosis in a Patient with Rheumatoid Arthritis |
| Q41455235 | Insight into Metabolic 1H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions |
| Q41921811 | JC Polyomavirus Attachment and Entry: Potential Sites for PML Therapeutics |
| Q97418947 | JC Polyomavirus, progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome: a review |
| Q35226750 | JC Virus PCR Detection Is Not Infallible: A Fulminant Case of Progressive Multifocal Leukoencephalopathy with False-Negative Cerebrospinal Fluid Studies despite Progressive Clinical Course and Radiological Findings |
| Q41339678 | JC polyomavirus reactivation is common following allogeneic stem cell transplantation and its preemptive detection may prevent lethal complications |
| Q40965913 | JC polyomavirus viremia and progressive multifocal leukoencephalopathy in human leukocyte antigen-sensitized kidney transplant recipients desensitized with intravenous immunoglobulin and rituximab |
| Q35586120 | JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis |
| Q91260333 | Lack of specific T- and B-cell clonal expansions in multiple sclerosis patients with progressive multifocal leukoencephalopathy |
| Q42362984 | Laminar Cortical Hypointensities in Susceptibility-Weighted Imaging in a Case of Progressive Multifocal Leukoencephalopathy. |
| Q39391443 | Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis |
| Q42155214 | Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia |
| Q33693085 | Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy |
| Q41361912 | MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. |
| Q41745436 | MRI pattern in asymptomatic natalizumab-associated PML. |
| Q33891255 | Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR) |
| Q33605681 | Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML). |
| Q26776234 | Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes |
| Q42363059 | Multidisciplinary Rehabilitation is Efficacious and Induces Neural Plasticity in Multiple Sclerosis even when Complicated by Progressive Multifocal Leukoencephalopathy |
| Q39211049 | Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications. |
| Q49596958 | Mystery Case: A 48-year-old woman with bizarre behavior, neurologic symptoms, and progressive decline |
| Q36389681 | Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers. |
| Q33754882 | Natalizumab in Multiple Sclerosis: Long-Term Management |
| Q38786252 | Natalizumab in relapsing-remitting multiple sclerosis |
| Q28555138 | Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry |
| Q86694924 | Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS |
| Q38221343 | Natalizumab: risk stratification of individual patients with multiple sclerosis |
| Q36330202 | Neurobehavioral Manifestations of Human Immunodeficiency Virus/AIDS: Diagnosis and Treatment |
| Q26781389 | Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities |
| Q41553443 | Neurological safety of fingolimod: An updated review |
| Q50604419 | Neuropsychological impairment in natalizumab-associated progressive multifocal leukoencephalopathy: implications for early diagnosis. |
| Q37201023 | Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate |
| Q26741723 | Oligodendrocyte Injury and Pathogenesis of HIV-1-Associated Neurocognitive Disorders |
| Q38690896 | Opportunistic Neurologic Infections in Patients with Acquired Immunodeficiency Syndrome (AIDS). |
| Q34562841 | Outcome and survival of asymptomatic PML in natalizumab-treated MS patients |
| Q32182145 | PET Imaging of 18F-FDG, 11C-methionine, 11C-flumazenil, and 11C-4DST in Progressive Multifocal Leukoencephalopathy |
| Q34650456 | PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation |
| Q40074322 | PML-IRIS in an HIV-2-infected patient presenting as Bell's palsy. |
| Q42248880 | Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy |
| Q52587612 | Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. |
| Q96953480 | Posterior Reversible Encephalopathy Syndrome (PRES): Pathophysiology and Neuro-Imaging |
| Q42650343 | Posterior fossa progressive multifocal leukoencephalopathy: first presentation of an unknown autoimmune disease |
| Q34505467 | Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy |
| Q39418067 | Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy |
| Q93109308 | Prevalence of Anti-JC Virus (JCV) Antibodies in the Multiple Sclerosis (MS) Population in Cyprus: A Retrospective Study |
| Q26766172 | Progressive Multifocal Leukoencephalopathy |
| Q91867877 | Progressive Multifocal Leukoencephalopathy Diagnosed by Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid in an HIV Patient |
| Q52584947 | Progressive Multifocal Leukoencephalopathy Following Combined Rituximab-Based Immune-Chemotherapy for Post-transplant Lymphoproliferative Disorder in a Renal Transplant Recipient: A Case Report. |
| Q30876283 | Progressive Multifocal Leukoencephalopathy Following Treatment with Rituximab in an HIV-Negative Patient with Non-Hodgkin Lymphoma. A Case Report and Literature Review. |
| Q36766244 | Progressive Multifocal Leukoencephalopathy and Systemic Lupus Erythematosus: Focus on Etiology |
| Q30245002 | Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals. |
| Q90529500 | Progressive Multifocal Leukoencephalopathy in Primary Immunodeficiencies |
| Q37475542 | Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod |
| Q61809978 | Progressive Multifocal Leukoencephalopathy in the Absence of Typical Radiological Changes: Can We Make a Diagnosis? |
| Q91830971 | Progressive Multifocal Leukoencephalopathy: Current Insights |
| Q36783178 | Progressive Right-Sided Hemiparesis in a Man With Sarcoidosis |
| Q55015964 | Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. |
| Q30235523 | Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency. |
| Q41155040 | Progressive multifocal leucoencephalopathy limited to the posterior fossa as first manifestation of HIV infection |
| Q40044199 | Progressive multifocal leukoencephalopathy 11 years after liver transplantation: a case report. |
| Q102220458 | Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease |
| Q54239221 | Progressive multifocal leukoencephalopathy associated with thymoma with immunodeficiency: a case report and literature review. |
| Q64264718 | Progressive multifocal leukoencephalopathy diagnosed by brain biopsy, not by the DNA test for JC Virus |
| Q92126833 | Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes |
| Q40641629 | Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression |
| Q41282310 | Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine. |
| Q38153637 | Progressive multifocal leukoencephalopathy in multiple sclerosis |
| Q39325788 | Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases |
| Q38689838 | Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. |
| Q57802122 | Progressive multifocal leukoencephalopathy unmasked by antiretroviral therapy for HIV |
| Q64892430 | Progressive multifocal leukoencephalopathy with extended natalizumab dosing. |
| Q90286870 | Progressive multifocal leukoencephalopathy: A 25-year retrospective cohort study |
| Q64232381 | Progressive multifocal leukoencephalopathy: a challenging diagnosis established at autopsy |
| Q30676296 | Progressive multifocal leukoencephalopathy: a rare infectious complication following allogeneic hematopoietic cell transplantation (HCT). |
| Q28083338 | Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate |
| Q58566596 | Quantitative electroencephalography supports diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy |
| Q90003732 | Rapid cognitive decline in a patient with chronic lymphocytic leukaemia: a case report |
| Q92527290 | Rare but not beyond care: a young female with altered mental status and seizures |
| Q42540004 | Reply to magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab |
| Q34542922 | Safety of monoclonal antibodies for the treatment of multiple sclerosis. |
| Q40222938 | Single-Molecule Sequencing Revealing the Presence of Distinct JC Polyomavirus Populations in Patients With Progressive Multifocal Leukoencephalopathy |
| Q38260098 | Sorting out the risks in progressive multifocal leukoencephalopathy |
| Q53442107 | Spinal cord progressive multifocal leukoencephalopathy detected premortem by MRI. |
| Q26780412 | Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group |
| Q50043312 | Susceptibility of Primary Human Choroid Plexus Epithelial Cells and Meningeal Cells to Infection by JC Virus. |
| Q93103835 | Tau-protein concentrations are not elevated in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy |
| Q42469455 | Teaching NeuroImages: epilepsia partialis continua revealing PML after allogenic stem cell transplantation |
| Q54263542 | The Benefit of Mirtazapine in the Treatment of Progressive Multifocal Leukoencephalopathy in a Young HIV-positive Patient: A Case Report. |
| Q64114443 | The Incidence and Predisposing Factors of John Cunningham Virus-Induced Progressive Multifocal Leukoencephalopathy in Southern Finland: A Population-Based Study |
| Q38115572 | The human JC polyomavirus (JCPyV): virological background and clinical implications |
| Q48254563 | The most fulminant course of the Marburg variant of multiple sclerosis-autopsy findings |
| Q50102128 | The national incidence of PML in Sweden, 1988-2013. |
| Q58864832 | The still under-investigated role of cognitive deficits in PML diagnosis |
| Q28088291 | The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research |
| Q33879159 | The use of natalizumab for multiple sclerosis |
| Q47812653 | To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. |
| Q90288758 | Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration |
| Q30249052 | Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine. |
| Q64274762 | Treatment of natalizumab-associated PML with filgrastim |
| Q38665891 | Treatment options for progressive multifocal leukoencephalopathy in HIV-infected persons: current status and future directions |
| Q38543193 | Triads in Ophthalmology: A Comprehensive Review |
| Q92904381 | Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab |
| Q34368638 | Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy |
| Q33875468 | Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown |
| Q34129550 | White matter signal abnormalities in children with suspected HIV-related neurologic disease on early combination antiretroviral therapy |
| Q88533703 | [Progressive multifocal leukoencephalopathy] |
Search more.